Sign In
Buy ATS
$28.85
-1.01 (-3.38%)
At Close: Jun 03, 2026
New Strong Sell Stocks for September 30th
05:35am, Monday, 30'th Sep 2024
ATS, AZUL and BW have been added to the Zacks Rank #5 (Strong Sell) List on September 30, 2024.
ATS Corporation: Diamond In The Rough
10:12am, Thursday, 26'th Sep 2024
ATS provides vertically integrated automation solutions, focusing on Life Sciences and F&B sectors, with a robust backlog and strategic acquisitions enhancing growth potential. The macroeconomic envir
New Strong Sell Stocks for September 13th
06:15am, Friday, 13'th Sep 2024
ATS, BMTX and B have been added to the Zacks Rank #5 (Strong Sell) List on September 13, 2024.
ATS to Participate in the Jefferies Industrials Conference
05:00pm, Monday, 19'th Aug 2024
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Andrew Hider, Chief Executive Officer and Ryan McLeod, Chief Financial
ATS Corporation: This High-Quality Compounder Is A Bargain At 16x Earnings
04:38pm, Monday, 19'th Aug 2024
ATS Corporation is a play on automation growth in manufacturing with exposure to electric vehicle battery outsourcing. The stock is down ~40% from its peak, but has potential for over 50% upside in a
ATS Corporation: Near Record Bookings In Q3 (Rating Upgrade)
10:35am, Tuesday, 13'th Aug 2024
ATS Corporation is a developer of automation technology with global operations and $3 billion in annual sales. Recent results showed a decline in revenue but strong performance in life sciences, with
ATS Corporation (ATS) Q1 2025 Earnings Call Transcript
02:55pm, Saturday, 10'th Aug 2024
ATS Corporation (NYSE:ATS ) Q1 2025 Results Conference Call August 8, 2024 8:30 AM ET Company Participants David Galison - Head of Investor Relations Andrew Hider - Chief Executive Officer Ryan McLeod
ATS (ATS) Lags Q1 Earnings Estimates
08:16am, Thursday, 08'th Aug 2024
ATS (ATS) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.51 per share a year ago.
Earnings Preview: ATS (ATS) Q1 Earnings Expected to Decline
11:06am, Thursday, 01'st Aug 2024
ATS (ATS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ATS Announces Dates of First Quarter Results Conference Call and Annual Meeting of Shareholders
06:45am, Monday, 22'nd Jul 2024
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) will report its financial results for the first quarter ended June 30, 2024, before markets
St Andrews, UK – 23nd May 2024 - Pneumagen, a clinical stage biotech company developing Neumifil (HEX17), a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respi
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
11:20am, Wednesday, 22'nd May 2024
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data pr
NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
02:15pm, Monday, 20'th May 2024
Dupixent ® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent sig
